Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
The STEADY-PD trial results
The results of the Phase lll STEADY-PD clinical trial have now been published.
A better delivery of Dopamine
People with Parkinson’s have a severe reduction in levels of a protein called dopamine in their brains. Lower levels of dopamine are associated with the motor symptoms of the condition (slowness and rigidity of movement). Doctors prescribe treatments that replace this lost dopamine as a…
3P: Parkinson Postdoc Program Seminars
Cure Parkinson’s, Van Andel Institute and World Parkinson Coalition Institute present: The 3P Parkinson Postdoc Program Seminars
Time to re-nurture neurturin?
A new research report suggests that a disappointing gene therapy treatment did have an effect inside the brain, which could now have important implications for future gene therapy trials.
Exenatide: further studies initiated
In 2012, Cure Parkinson’s initiated the International Linked Clinical Trials (iLCT) programme to focus on identifying and prioritising potentially disease-modifying therapies for Parkinson’s. The first drug to be prioritised within the programme by the iLCT committee was a diabetes medication called exenatide. Since then, Cure Parkinson’s has…